Isorhynchophylline treatment improves the amyloid-β-induced cognitive impairment in rats via inhibition of neuronal apoptosis and tau protein hyperphosphorylation

Journal of Alzheimer's Disease

Volumn 39, Issue 2, 2014, Pages 331-346

  Xian, Yan Fang ^a   Mao, Qing Qiu ^a   Wu, Justin C Y ^a   Su, Zi Ren ^b   Chen, Jian Nan ^b   Lai, Xiao Ping ^b   Ip, Siu Po ^a   Lin, Zhi Xiu ^a  

^a and Hong Kong Branch of CAS Center for Excellence in Animal Evolution and Genetics   (Hong Kong)

^b GUANGZHOU UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

Amyloid ; apoptosis; isorhynchophylline; PI3K Akt signaling pathway; spatial memory; tau protein hyperphosphorylation

Indexed keywords

AMYLOID BETA PROTEIN[25-35]; CASPASE 3; CASPASE 9; CYTOCHROME C; GLYCOGEN SYNTHASE KINASE 3BETA; ISORHYNCHOPHYLLINE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN BAX; PROTEIN BCL 2; PROTEIN KINASE B; TAU PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; COGNITION; COGNITIVE DEFECT; DOWN REGULATION; DRUG MECHANISM; DRUG STRUCTURE; ENZYME ACTIVITY; HIPPOCAMPAL CA1 REGION; HIPPOCAMPUS; MALE; NERVE CELL; NEUROPROTECTION; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; PYRAMIDAL NERVE CELL; RAT; SIGNAL TRANSDUCTION;

AMYLOID-Β; APOPTOSIS; ISORHYNCHOPHYLLINE; PI3K/AKT SIGNALING PATHWAY; SPATIAL MEMORY; TAU PROTEIN HYPERPHOSPHORYLATION;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CASPASES; COGNITION DISORDERS; CYTOCHROMES C; DISEASE MODELS, ANIMAL; GLYCOGEN SYNTHASE KINASE 3; HIPPOCAMPUS; INDOLE ALKALOIDS; MALE; MAZE LEARNING; NEURONS; NEUROPROTECTIVE AGENTS; PEPTIDE FRAGMENTS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; PROTO-ONCOGENE PROTEINS C-BCL-2; RATS; RATS, SPRAGUE-DAWLEY; SPACE PERCEPTION; TAU PROTEINS;

EID: 84893931177     PISSN: 13872877     EISSN: 18758908     Source Type: Journal    
DOI: 10.3233/JAD-131457     Document Type: Article

References (79)

1. Tabner BJ,Turnbull S, EI-AgnafOM,AllsopD(2002) Formation of hydrogen peroxide and hydroxyl radicals from A(beta) and alpha-synuclein as a possible mechanism of cell death in Alzheimer's disease and Parkinson's disease. Free Radic Biol Med 32, 1076-1083.
2. Hellstrom-Lindahl E, Viitanen M, Marutle A (2009) Comparison of Abeta levels in the brain of familial and sporadic Alzheimer's disease. Neurochem Int 55, 243-252.
3. Hongpaisan J, Sun MK, Alkon DL (2011) PKC ε activation prevents synaptic loss, Aβ elevation, and cognitive deficits in Alzheimer's disease transgenic mice. J Neurosci 31, 630-643.
4. Jawhar S, Wirths O, Schilling S, Demuth HU, Bayer TA (2011) Overexpression of glutaminyl cyclase, the enzyme responsible for pyroglutamate Abeta formation, induces behavioral deficits, and glutaminyl cyclase knock-out rescues the behavioral phenotypes in 5XFAD mice. J Biol Chem 286, 4454-4460.
5. Limon ID, Mendieta L, Díaz A, Chamorro G, Espinosa B, Zenteno E, Guevara J (2009) Neuroprotective effect of alpha-asarone on spatial memory and nitric oxide levels in rats injected with amyloid-β(25-35). Neurosci Lett 453, 98-103.
6. Liu R, Zou LB, Fu JY, Lu QJ (2010) Effects of liquiritigenin treatment on the learning and memory deficits induced by amyloid β-peptide (25-35) in rats. Behav Brain Res 210, 24-31.
7. Peng Y, Xing C, Xu S, Lemere CA, Chen G, Liu B, Wang L, Feng Y, Wang X (2009) L-3-n-butylphthalide improves cognitive impairment induced by intrcerebroventricular infusion of amyloid-β peptide in rats. Eur J Pharmacol 621, 38-45.
8. Zussy C, Brureau A, Delair B, Marchal S, Keller E, Ixart G, Naert G, Meunier J, Chevallier N, Maurice T, Givalois L (2011) Time-course and regional analyses of the physiopathological changes induced after cerebral injection of an amyloid β fragment in rats. Am J Pathol 179, 315-334.
9. Hiramatsu M, Watanabe M, Baba S, Kojima R, Nabeshima T (2004) Alpha 7-type nicotinic acetylcholine receptor and prodynorphin mRNA expression after administration of (-)-nicotine and U-50, 488H in beta-amyloid peptide (25-35)-treated rats. Ann N Y Acad Sci 1025, 508-514.
10. Tran MH, Yamada K, Olariu A, Mizuno M, Ren XH, Nabeshima T (2001) Amyloid beta-peptide induces nitric oxide production in rat hippocampus: Association with cholinergic dysfunction and amelioration by inducible nitric oxide synthase inhibitors. FASEB J 15, 1407-1409.
11. Howard R, McShane R, Lindesay J, Ritchie C, Baldwin A, Barber R, Burns A, Dening T, Findlay D, Holmes C, Hughes A, Jacoby R, Jones R, Jones R, McKeith I, Macharouthu A, O'Brien J, Passmore P, Sheehan B, Juszczak E, Katona C, Hills R, Knapp M, Ballard C, Brown R, Banerjee S, Onions C, Griffin M, Adams J, Gray R, Johnson T, Bentham P, Phillips P (2012) Donepezil and memantine for moderate-to-severe Alzheimer's disease. N Engl J Med 366, 893-903.
12. Olivares D, Deshpande VK, Shi Y, Lahiri DK, Greig NH, Rogers JT, Huang X (2012) N-Methyl D-Aspartate (NMDA) Receptor antagonists and memantine treatment for Alzheimer's disease, vascular dementia and Parkinson's disease. Curr Alzheimer Res 9, 746-758.
13. Inglis F (2002) The tolerability and safety of cholinesterase inhibitors in the treatment of dementia. Int J Clin Pract Suppl 127, 45-63.
14. Oken BS, Storzbach DM, Kaye JA (1998) The efficacy of Ginkgo biloba on cognitive function in Alzheimer disease. Arch Neurol 55, 1409-1415.
15. Akhondzadeh S, Abbasi SH (2006) Herbal medicine in the treatment of Alzheimer's disease. Am J Alzheimers Dis Other Dement 21, 113-118.
16. Wu TY, Chen CP, Jinn TR (2011) Traditional Chinese medicines and Alzheimer's disease. Taiwan J Obstet Gynecol 50, 131-135.
17. Xian YF, Lin ZX, Zhao M, Mao QQ, Ip SP, Che CT (2011) Uncaria rhynchophylla ameliorates cognitive deficits induced by D-galactose in rats. Planta Med 77, 1977-1983.
18. Kang TH, Murakami Y, Takayama H, Kitajima M, Aimi N, Watanabe H, Matsumoto K (2004) Protective effect of rhynchophylline and isorhynchophylline on in vitro ischemiainduced neuronal damage in the hippocampus: Putative neurotransmitter receptors involved in their action. Life Sci 76, 331-343.
19. Yuan D, Ma B, Yang JY, Xie YY,Wang L, Zhang LJ, Kano Y, Wu CF (2009) Anti-inflammatory effects of rhynchophylline and isorhynchophylline in rat N9 microglial cells and the molecular mechanism. Int Immunopharmacol 9, 1549-1554.
20. Shimada Y, Goto H, Itoh T, Sakakibara I, Kubo M, Sasaki H, Terasawa K (1999) Evaluation of the protective effects of alkaloids isolated from the hooks and stems of Uncaria sinensis on glutamate-induced neuronal death in cultured cerebellar granule cells from rats. J Pharm Pharmacol 51, 715-722.
21. Kanatani H,Kohda H,Yamasaki K, Hotta I, NakataY, Segawa T, Yamanaka E, Aimi N, Sakai S (1985) The active principle of the branchlets and hook of Uncaria sinensis Oliv. examined with a 5-hydroxytryptamine receptor-binding assay. J Pharm Pharmacol 37, 401-404.
22. Matsumoto K, Morishige R, Murakami Y, Tohda M, Takayama H, Sakakibara I, Watanabe H (2005) Suppressive effects of isorhynchophylline on 5-HT2A receptor function in the brain: Behavioural and electrophysiological studies. Eur J Pharmacol 517, 191-199.
23. Lu JH, Tan JQ, Durairajan SS, Liu LF, Zhang ZH, Ma L, Shen HM, Chan HY, Li M (2012) Isorhynchophylline, a natural alkaloid, promotes the degradation of alpha-synuclein in neuronal cells via inducing autophagy. Autophagy 8, 98-108.
24. Xian YF, Lin ZX, Mao QQ, Ip SP, Su ZR, Lai XP (2012) Protective effect of isorhynchophylline against β-amyloidinduced neurotoxicity in PC12 cells. Cell Mol Neurobiol 32, 353-360.
25. Xian YF, Lin ZX, Mao QQ, Zhao M, Hu Z, Ip SP (2012) Bioassay-guided isolation of neuroprotective compounds from Uncaria rhynchophylla against beta-amyloid-induced neurotoxicity in PC12 cells. Evid Based Complement Alternat Med 2012, 802625.
26. Huang B, Wu Q, Wen G, Lu Y, Shi J (2001) The distribution of isorhynchophylline in the tissues of the rats and the determination of its plasma half-time. Acta Academiae Medicinae Zunyi 24, 119-120.
27. Haginiwa J, Sakai S, Aimi N, Yamanaka E, Shinma N (1973) Studies of plants containing indole alkaloids. 2. On the alkaloids of Uncaria rhynchophylla Miq. Yakugaku Zasshi 93, 448-452.
28. Paxinos G, Watson C (1998) The rat brain in stereotaxic coordinates, Academic Press, New York, NY.
29. Li J,Wang G, Liu J, Zhou L, Dong M,Wang R, Li X, Li X, Lin C, Niu Y (2010) Puerarin attenuates amyloid-beta-induced cognitive impairment through suppression of apoptosis in rat hippocampus in vivo. Eur J Pharmacol 649, 195-201.
30. West MJ, Gunderson HJ (1990) Unbiased stereological estimation of the number of neurons in the human hippocampus. J Comp Neurol 296, 1-22.
31. Tang VW, Eisenbrand G (1992) Chinese Drugs of Plant Origin. Chemistry, Pharmacology, and Use in Traditional and Modern Medicine, Springer-Verlag, Berlin, pp.
32. Shi J, Liu G, Wu Q, Zhang W, Huang X (1989) Hypotensive and hemodynamic effects of isorhynchophylline in conscious rats and anaesthetized dogs. Chin J Pharmacol Toxicol 3, 205-211.
33. Hu XN, Wu Q, Shi JS (1994) Effects of rhynchophylline and isorhynchophylline on the contractile responses of rat isolated mesenteric arteries and tail artery. Acta Acad Med Zunyi 17, 7-10.
34. Huang B,Wu Q,WenG, LuY, Shi J (2001) Effects of isorhynchophylline concentration in plasma on heart rate and His bundle electrograms in the rabbits. Acta Acad Med Zunyi 24, 10-11.
35. Sakakibara I, Terabayashi S, Kubo M, Higuchi M, Komatsu Y, Okada M, Taki K, Kamei J (1999) Effect on locomotion of indole alkaloids from the hooks of Uncaria plants. Phytomedicine 6, 163-168.
36. Mohamed AF, Matsumoto K, Tabata K, Takayama H, Kitajima M, Watanabe H (2000) Effects of Uncaria tomentosa total alkaloid and its components on experimental amnesia in mice: Elucidation using the passive avoidance test. J Pharm Pharmacol 52, 1553-1561.
37. Kang TH, Murakami Y, Matsumoto K, Takayama H, Kitajima M, Aimi N, Watanabe H (2002) Rhynchophylline and isorhynchophylline inhibit NMDA receptors expressed in Xenopus oocytes. Eur J Pharmacol 455, 27-34.
38. Ozaki Y (1989) [Pharmacological studies of indole alkaloids obtained from domestic plants, Uncaria rhynchophylla Miq. and Amsonia elliptica Roem. et Schult] Japanese. Nihon Yakurigaku Zasshi 94, 17-26.
39. Pfizer Material Safety Data Sheet (2010) Donepezil hydrochloride orally disintegrating tablets, http://www.pfizer. com/files/products/material safety data/PZ00471.pdf.
40. Be-Long Corporation Material Safety Data Sheet. Galantamine hydrobromide MSDS, http://www.galantaminehydrobromide. com/upfiles/file/galantamine- hydrobromidemsds. pdf.
41. Novartis New Zealand Limited Material Safety Data Sheet (2012) Exelon®, rivastigmine, http://www.medsafe.govt.nz/profs/datasheet/e/ Exeloncap.pdf.
42. Gao Y, Chen HJ, Qian LH, Jiang MH (2005) Toxic reaction of memantine in neonatal rats after repetitive administration. Chin J Clin Rehab 47, 107-109.
43. Greenberg BD, Savage MJ, Howland DS, Ali SM, Siedlak SL, Perry G, Siman R, Scott RW (1996) APP transgenesis: Approaches toward the development of animal models for Alzheimer disease neuropathology. Neurobiol Aging 17, 153-171.
44. Kubo T, Nishimura S, Kumagae Y, Kaneko I (2002) In vivo conversion of of racemized beta-amyloid ([D-Ser 26] A beta 1-40) to truncated and toxic fragment ([D-Ser 26] A beta 25-35) and fragment presence in the brains of Alzheimer's patients. J Neurosci Res 70, 474-483.
45. Alkam T, Nitta A, Mizoguchi H, Saito K, Seshima M, Itoh A, Yamada K, Nabeshima T (2008) Restraining tumor necrosis factor-alpha by thalidomide prevents the amyloid β-induced impairment of recognition memory in mice. Behav Brain Res 189, 100-106.
46. Nitta A, Itoh A, Hasegawa T, Nabeshima T (1994) Betaamyloid protein-induced Alzheimer's disease animal model. Neurosci Lett 170, 63-66.
47. Zola-Morgan S, Squire LR, Amaral DG (1986) Human amnesia and the medial temporal region: Enduring memory impairment following a bilateral lesion limited to field CA1 of the hippocampus. J Neurosci 6, 2950-2967.
48. Kiyota Y, Miyamoto M, Nagaoka A (1991) Relationship between brain damage and memory impairment in rats exposed to transient ischemia. Brain Res 538, 295-302.
49. Selkoe DJ (2001) Alzheimer's disease: Genes, proteins, and therapy. Physiol Rev 81, 741-766.
50. Braak H, Braak E (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 82, 239-259.
51. Campbell S, Macqueen G (2004) The role of the hippocampus in the pathophysiology of major depression. J Psychiatry Neurosci 29, 417-426.
52. Strephanichev M, Zdobnova I, Zarubenko I, Lazareva N, Gulyaeva N (2006) Studies of the effects of central administration of β-amyloid peptide (25-35): Pathomorphological changes in the hippocampus and impairment of spatial memory. Neurosci Behav Physiol 36, 101-106.
53. McDonald RJ, White NM (1994) Parallel information processing in the water maze: Evidence for independent memory systems involving dorsal striatum and hippocampus. Behav Neural Biol 61, 260-270.
54. Lauzon RJ, Ishizuka KJ, Weissman IL (2002) Cyclical generation and degeneration of organs in a colonial urochordate involves crosstalk between old and new: A model for development and regeneration. Dev Biol 249, 333-348.
55. Anderson AJ, Stoltzner S, Lai F, Su J, Nixon RA (2000) Morphological and biochemical assessment of DNA damage and apoptosis in Down syndrome and Alzheimer disease, and effect of postmortem tissue archival in TUNEL. Neurobiol Aging 21, 511-524.
56. Gervais FG, Xu D, Robertson GS, Vaillancourt JP, Zhu Y, Huang J, LeBlanc A, Smith D, Rigby M, Shearman MS, Clarke EE, Zheng H, Van Der Ploeg LH, Ruffolo SC, Thornberry NA, Xanthouclakis S, Zamboni RJ, Roy S, Nicholson DW (1999) Involvement of caspases in proteolytic cleavage of Alzheimer's amyloid-beta precursor protein and amyloidogenic A beta peptide formation. Cell 97, 395-406.
57. Abad MA, Enguita M, DeGregorio-Rocasolano N, Ferrer I, Trullas R (2006) Neuronal pentraxin 1 contributes to the neuronal damage evokes by amyloid-beta and is overexpressed in dystrophic neuritis in Alzheimer's brain. J Neurosci 26, 12735-12747.
58. Li J, Hu J, Shao B, ZhouW, Cui Y, Dong C, Ezoulin JM, Zhu X, DingW, Heymans F, ChenH(2009) Protection of PMS777, a new AChE inhibitor with PAF antagonism against amyloidbeta-induced neuronal apoptosis and neuroinflammation. Cell Mol Neurobiol 29, 589-595.
59. Yao M, Nguyen TV, Pike CJ (2005) Beta-amyloidinduced neuronal apoptosis involves c-Jun N-terminal kinase-dependent downregulation of Bcl-w. J Neurosci 25, 1149-1158.
60. Di Segni A, Shaharabani E, Stein R, Pinkas-Kramarski R (2005) Neuregulins rescue PC12-ErbB-4 cells from cell death induced by beta-amyloid peptide: Involvement of PI3K and PKC. J Mol Neurosci 26, 57-69.
61. Jang JH, Surh YJ (2004) Bcl-2 protects against Abeta (25-35)-induced oxidative PC12 cell death by potentiation of antioxidant capacity. Biochem Biophys Res Commun 320, 880-886.
62. Kostic V, Przedborski S, Flaster E, Sternic N (1991) Early development of levodopa-induced dyskinesias and response fluctuations in young-onset Parkinson's disease. Neurology 41, 202-205.
63. Yang L, Matthews RT, Schulz JB, Klockgether T, Liao AW, Martinou JC, Penney JB Jr, Hyman BT, Beal MF (1998) 1-Methyl-4-phenyl-1,2,3,6- tetrahydropyride neurotoxicity is attenuated in mice overexpressing Bcl-2. J Neurosci 18, 8145-8152.
64. Cardone MH, Roy N, Stennicke HR, Salvesen GS, Franke TF, Stanbridge E, Frisch S, Reed JC (1998) Regulation of cell death protease caspase-9 by phosphorylation. Science 282, 1318-1321.
65. Zörnig M, Hueber A, Baum W, Evan G (2001) Apoptosis regulators and their role in tumorigenesis. Biochim Biophys Acta 1551, F1-F37.
66. Alonso AC, Grundke-Iqbal I, Iqbal K (1996) Alzheimer's disease hyperphosphorylation tau sequesters normal tau into tangles of filaments and disassembles microtubules. Nat Med 2, 783-787.
67. Zeng KW, Ko H, Yang HO, Wang XM (2010) Icariin attenuates β-amyloid-induced neurotoxicity by inhibition of tau protein hyperphosphorylation in PC12 cells. Neuropharmacology 59, 542-550.
68. ZhouXW, Li X, Bjorkdahl C, Sjogren MJ, Alafuzoff I, Soininen H, Grundke-Iqbal I, Iqbal K, Winblad B, Pei JJ (2006) Assessments of the accumulation severities of amyloi betaprotein and hyperphosphorylated tau in the medial temporal cortex of control and Alzheimer's brain. Neurobiol Dis 22, 657-668.
69. Hooper C, Killick R, Lovestone S (2008) The GSK3 hypothesis of Alzheimer's disease. J Neurochem 104, 1433-1439.
70. Iqbal K, Grundke-Iqbal I (2007) Developing pharmacological therapies for Alzheimer disease. Cell Mol Life Sci 64, 2234-2244.
71. Bhat RV, Budd Haeberlein SL, Avila J (2004) Glycogen synthase kinase 3: A drug target for CNS therapies. J Neurochem 89, 1313-1317.
72. Grimes CA, Jope RS (2001) The multifaceted roles of glycogen synthase kinase 3beta in cellular signaling. Prog Neurobiol 65, 391-426.
73. Beurel E, Jope RS (2006) The paradoxical pro-and antiapoptotic actions of GSK3 in the intrinsic and extrinsic apoptosis signaling pathways. Prog Neurobiol 79, 173-189.
74. Takashima A, Noguchi K, Michel G, Mercken M, Hoshi M, Ishiguro K, Imahori K (1996) Exposure of rat hippocampal neurons to amyloid β peptide (25-35) induces the inactivation of phosphatidyl inositol-3 kinase and the activation of tau protein kinase I/glycogen sythase kinase-3β. Neurosci Lett 203, 33-36.
75. Annika R, Nenad B, Inga V, Bengt W, Rivka R, Richard CF (2004) Akt activity in Alzheimer's disease and other neurodegenerative disorders. Neuroreport 15, 955-959.
76. Franke TF, Hornik CP, Segev I, Shostak GA, Sugimoto C (2003) PI3K/Akt and apoptosis: Size matters. Oncogene 22, 8983-8998.
77. Lee HK, Kumar P, Fu Q, Rosen KM, Querfurth HW (2009) The insulin/Akt signaling pathway is targeted by intracecellular beta-amyloid. Mol Biol Cell 20, 1533-1544.
78. Rickle A, Bogdanovic N, Volkman I, Winblad B, Ravid R, Cowburn RF (2004) Akt activity in Alzheimer's disease and other neurodegeneration disorders. Neuroreport 15, 955-959.
79. Salkovic-Petrisic M, Tribl F, Schmidt M, Hoyer S, Riederer P (2006) Alzheimer-like changes in protein kinase B and glycogen synthase kinase-3 in rat frontal cortex and hippocampus after damage to the insulin signaling pathway. J Neurochem 96, 1005-1015.